Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders. - Wikidata - thesis-toulmin - TriplyDB

Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders.

Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders.

http://www.wikidata.org/entity/Q36484413

about

The Role of Amyloid-β Oligomers in Toxicity, Propagation, and Immunotherapy Molecular Pathological Classification of Neurodegenerative Diseases: Turning towards Precision Medicine Bifunctional Anti-Non-Amyloid Component α-Synuclein Nanobodies Are Protective In Situ.Review: Novel treatment strategies targeting alpha-synuclein in multiple system atrophy as a model of synucleinopathy Antibody Engineering & Therapeutics 2016: The Antibody Society's annual meeting, December 11-15, 2016, San Diego, CA Nitric Oxide: Exploring the Contextual Link with Alzheimer's Disease Cognitive decline in Parkinson disease.Oligomeropathies and pathogenesis of Alzheimer and Parkinson's diseases.Neuroprotection by Epigenetic Modulation in a Transgenic Model of Multiple System Atrophy Anti-tau antibody administration increases plasma tau in transgenic mice and patients with tauopathy.Recombinant Antibody Fragments for Neurodegenerative Diseases.Drugs in Clinical Trials for Alzheimer's Disease: The Major Trends.New Therapeutic Strategies for Lewy Body Dementias.Statins are ineffective at reducing neuroinflammation or prolonging survival in scrapie-infected mice.Nanobodies raised against monomeric ɑ-synuclein inhibit fibril formation and destabilize toxic oligomeric species.Progress toward an integrated understanding of Parkinson's disease.α-synuclein conformational antibodies fused to penetratin are effective in models of Lewy body disease.Extracellular truncated tau causes early presynaptic dysfunction associated with Alzheimer's disease and other tauopathies Neuro-Immunotherapies: A 30-year Retrospective of an Overwhelming Success and a Brighter Future.Amyloid β oligomers (AβOs) in Alzheimer's disease.Combined Active Humoral and Cellular Immunization Approaches for the Treatment of Synucleinopathies.Immunization with α-synuclein/Grp94 reshapes peripheral immunity and suppresses microgliosis in a chronic Parkinsonism model.Vaccination strategies in tauopathies and synucleinopathies.Evaluation of multifunctional synthetic tetralone derivatives for treatment of Alzheimer's disease.Looking at the Disordered Proteins through the Computational Microscope.Aggregated SOD1 causes selective death of cultured human motor neurons Immunotherapy targeting toll-like receptor 2 alleviates neurodegeneration in models of synucleinopathy by modulating α-synuclein transmission and neuroinflammation

P2860

Q26747107-9ED8EB90-A697-4271-BEFD-62049E86BD6B Q26768648-F1BBC2FB-B458-4970-B872-3BFD3803EBB3 Q36185625-0E7033F6-67A7-4C70-96C8-31C3484B37C5 Q36672116-74C353FB-A094-4657-81E2-5B0F873FE34D Q37397677-A961ED87-DB83-4F22-98A7-2C5985955C4F Q37554157-2C9DCD94-6CDD-4C00-85F8-D0A40AECC8EC Q38751099-92E15631-96DA-4C7B-A21C-16E5A959E34D Q38794219-03FB497C-FB31-483C-81EC-8E2AB1BC0CAA Q38809733-9E54A953-4CD9-4850-A800-4E390D1B428F Q38829673-8A533E0D-C5EA-444E-985E-0A300AEED9B1 Q38970823-02227A03-CA2C-43B0-967E-A9D0AE7C8F5D Q39022532-6610BABC-3804-484E-86C9-E3F27D4232A2 Q39456457-9F659FBC-08AB-4A5D-96B1-CE41DFEB6495 Q40101603-D02B6148-A13D-4122-89B0-59B2F86DA367 Q40968608-0921105E-BAE3-44E1-AA14-36098A4C3237 Q41012014-EFE5F9B5-412A-4C0A-BE22-547C443A082D Q41117719-8A52B8BA-3D79-4D6C-8D83-01C49A0C8F27 Q42371467-8D4A52F1-9FDB-41A5-BD56-ABDEA1EB67C3 Q43077236-84AF4DA8-4D1B-45B5-B7C3-6E164AE58857 Q47339779-C90BEBC3-5CA4-4D85-860D-6080B1293956 Q47563994-2AB45F32-BD85-43AC-9349-2930EFFE84C1 Q47662675-646F7382-A67C-4607-8DC4-00C413986BD1 Q47860105-F0E6B262-565D-4E05-AFE5-68EC1C27CE2D Q51109990-F4225751-90E7-4DED-97AB-5E08351F6E1F Q55044856-FF126D69-0213-4C9F-B1F6-EC54823A9307 Q58608836-0B9FC7D5-C30C-469A-8DDC-B6970D148812 Q58793525-B8DFD90F-8D34-4671-A393-5E1827DBF52C

P2860

Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders.

http://www.wikidata.org/entity/Q36484413

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Immunotherapeutic Approaches T ...... f Neurodegenerative Disorders.

@ast

Immunotherapeutic Approaches T ...... f Neurodegenerative Disorders.

@en

type

label

Immunotherapeutic Approaches T ...... f Neurodegenerative Disorders.

@ast

Immunotherapeutic Approaches T ...... f Neurodegenerative Disorders.

@en

prefLabel

Immunotherapeutic Approaches T ...... f Neurodegenerative Disorders.

@ast

Immunotherapeutic Approaches T ...... f Neurodegenerative Disorders.

@en

P1433

Q36484413-D49474B2-0496-4464-A013-FAC559E6837C

P1476

Q36484413-69B045C9-ADFD-47F1-9BD5-53A3DF60EF22

P2093

Q36484413-603D8169-F519-4785-9B27-E9C3981E9F95

Q36484413-FCB7D762-9611-4DF4-A587-7A27BD907094

P2860

Q36484413-001F731C-1B33-48CB-B02B-A74C76A47BBA

Q36484413-01ADC58D-15C0-444A-9063-1EB18CF3B250

Q36484413-0483B9C0-5A37-4F9F-B45E-FADA9BF37FE3

Q36484413-048877F8-736A-485B-8460-D2393E278991

Q36484413-04B8C927-20E6-4EDE-863E-BD34E16FCA64

Q36484413-054F0974-B781-401C-924E-53257AE01F90

Q36484413-09B88D9B-BC22-4878-BDE9-564522751DA6

Q36484413-0C17810B-38E2-4625-AE78-430A67BEAB49

Q36484413-0E20B42E-0885-44FF-9AAA-91D40732F933

Q36484413-0F577E81-1B72-4240-AFB9-79820F115C48

P2888

Q36484413-E3EE4ADD-16D6-494F-ADB1-3F8D675E75F3

P304

Q36484413-266DAD57-A19F-43BA-B215-33C13EBECA0D

P31

Q36484413-BA89C42A-8D8B-4FE3-A71A-B60BAEF5E493

P356

Q36484413-62B734AA-7294-4EDC-9551-7142D0583B74

P433

Q36484413-B2A510D8-2330-4857-A246-6D9D44E98C8F

P478

Q36484413-ACC34AB4-A941-43C2-9B60-4E16B4F535B7

P50

Q36484413-D9E13D1F-9C01-4C2E-818F-14808F0F0304

P577

Q36484413-82D1B8FF-6F39-4C31-85AC-0800EE08A4D6

P698

Q36484413-EB95A91A-BB16-4C4B-AE2C-7208085AABBD

P921

Q36484413-994B17DE-448B-47ED-AE85-A51C6E885200

Q36484413-D8A79984-B6DB-4EC1-A010-883727A1E2FD

Q36484413-F8F91477-02F0-4B72-8A78-7844F2C9C155

P932

Q36484413-4023108A-45FD-4389-A123-3ABB091081E4

P356

S13311-015-0397-Z

P1433

Neurotherapeutics

P1476

Immunotherapeutic Approaches T ...... f Neurodegenerative Disorders.

@en

P2093

Brian Spencer

http://www.w3.org/2001/XMLSchema#string

Elvira Valera

http://www.w3.org/2001/XMLSchema#string

P2860

Role of Protein Aggregation in Mitochondrial Dysfunction and Neurodegeneration in Alzheimer's and Parkinson's Diseases

Inhibition and disaggregation of α-synuclein oligomers by natural polyphenolic compounds

Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease

α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation

Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein

Implications of glial nitric oxide in neurodegenerative diseases

Tau clearance mechanisms and their possible role in the pathogenesis of Alzheimer disease

Tau-targeted treatment strategies in Alzheimer's disease

Passive immunization with phospho-tau antibodies reduces tau pathology and functional deficits in two distinct mouse tauopathy models

Does neuroinflammation fan the flame in neurodegenerative diseases?

P2888

s13311-015-0397-z

P304

179-189

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S13311-015-0397-Z

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P50

Eliezer Masliah

P577

2015-10-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26494242

http://www.w3.org/2001/XMLSchema#string

P921

neurodegeneration

P932

4720672

http://www.w3.org/2001/XMLSchema#string